A 26-year old Chinese lady two years ago had a pregnancy. At week 15 of gestation she touched a solid tumor in her left breast. Physical examination showed that the left breast mass was the size of a peanut, with milk overflow, no tenderness, and no apparent depression or bumped on the breast surface. Breast ultrasound showed hyperplasia of mammary glands, and low echo of the left breast, 12*8mm, 11*7mm, breast imaging reporting and data system (BI-RADS) 4a grade. The oncologist suggested reexamination after three months. The patient realized that the breast mass gradually increased, so she saw a doctor again in a large grade 3A hospital. Needle aspiration cytology of the left breast tumor was performed on March 14, 2019, and cancer cells were detected. Using breast ultrasound, a solid nodule was seen in the lower left breast quadrant, 18*13mm, clear boundary, lobulated, BI-RADS 3 grade. A solid cystic nodule, 10*8mm, was found, and a solid area could be seen in it, range about 4*3mm, BI-RADS 4a. Oncologists recommended that the patient should terminate the pregnancy.
Cesarean section was performed at 32 weeks and four days of pregnancy in the Beijing Obstetrics and Gynecology Hospital, Capital Medical University. The boy is healthy by now. At the same time of the cesarean section, the ovarian tissue biopsy was taken for OTC to preserve fertility and ovarian function. The amount of ovarian tissue taken from one side was 1/2, from the other was 1/3 of the ovary. The condition of fresh ovarian tissue was good, with a corpus luteum and rich blood vessels.
The ovarian tissue was successfully processed and slow-programmatically cryopreserved in ovarian tissue cryobank, and fresh cortex viability and morphology assessment was performed. The methods description was consistent with the previously published article [10, 11]. A total of 23 pieces of the ovarian cortex were frozen. The number of follicles in a round cortical piece of 2 mm is about 45, and it is estimated that 13000 follicles have been frozen for the patient. The images of follicular viability are shown in Fig. 1, and the images of HE staining in the cortex are shown in Fig. 2.
A biopsy of the left breast tumor was performed on April 18, 2019. Pathological findings showed that (breast tissue) invasive micropapillary carcinoma of the breast, immunohistochemical results: estrogen receptor (ER) (weak-medium positive, 10%), progesterone receptor (PR) (-), androgen receptor (AR) (weak-medium positive, 80%), Human epidermal growth factor receptor 2 (HER-2) (3 +). Ki-67 (index 30%), p53 (+), Cytokeratin 14 (CK14) (-), D2-40 (-), Epithelial membrane antigen (EMA) (+), CK5/6 (-), Epidermal growth factor receptor (EGFR) (-), Synaptophysin (Syn) (-), chromogranin A (CgA) (-). A left axillary sentinel lymph node biopsy was performed on April 24, 2019. Pathology showed that the metastatic carcinoma of the lymph node (left sentinel) (2 positives in 3) and the isolated tumor cells could be seen in the capsule of the other lymph node.
Neoadjuvant chemotherapy before breast surgery was given. The first chemotherapy regimen was docetaxel 120mg, epirubicin 110mg, and cyclophosphamide 900mg, q3w. Starting after the first course of chemotherapy, injections of goserelin acetate every 28 days, 3.6mg, were given, planned to continue for five years. There was no menstruation until now from the beginning of chemotherapy. According to the results of immunohistochemistry, the 2nd-6th chemotherapy regimen was adjusted as follows: docetaxel 110mg and carboplatin 500mg. Targeted therapy, trastuzumab, first dose was 17ml, then changed to 13ml. A total of 6 times of targeted therapy were performed before breast surgery.
Ultrasonographic examination of breast and axillary lymph nodes before breast surgery showed that low echo was seen at the edge of the gland in the direction of 6–7 o'clock in the left breast, 19*16*8mm. The boundary was unclear, and dotted strong echo was diffused in the left breast, BI-RADS 6.
Simple left mastectomy (preserving nipple-areola) and left axillary lymph node dissection were performed on September 10, 2019. Left breast reconstruction + acellular allogenic dermis implantation + dilator implantation was performed after breast surgery. Pathological report: In (left breast) breast tissue could be seen few invasive carcinomas (the largest 7mm), and a vascular tumor thrombus, the bottom cutting edge not special, lymph nodes showing chronic inflammation (left axilla 0/18). Immunohistochemical results showed: ER (weak positive, 10%), PR (-), AR (weak positive, 90%), Her-2 (3 +), Ki-67 (index25%), p53 (scattered +), EGFR (-), CK14 (-), CK5/6 (-), p63 (-), CgA (-), Syn (-), EMA (+).
After breast surgery, fixed-field intensity-modulated radiation therapy was performed with a 6MV-X line. 95% of the plan clinical tumor volume included left upper and lower clavicle, chest wall, dose 46Gy/23 times (2Gy/f), 5 f / w, filler bolus 0.5cm.
Fourteen courses of trastuzumab after surgery, and then pertuzumab + trastuzumab 13ml double targeted therapy for one year were performed, about 17 courses. After breast surgery, the injection of goserelin acetate was continued every 28 days, which is planned to last for five years. The endocrine therapy using anastrozole, a potent aromatase inhibitor, is scheduled to last also for five years.
The serum hormone levels before OTC and one year, 1.5 years, 2 years, and 2.2 years after OTC are shown in Table 1. At present, it seems that the AMH level of the patients is in the normal range, and the levels of FSH, LH, and E2 are all at a low level.
Table 1
Hormone levels of before and after cryopreservation
| 2019.04.08 (before OTC) | 2020.05.08 (1 year after OTC) | 2020.10.12 (1.5 years after OTC) | 2021.03.17 (2 years after OTC) | 2021.06.18 (2.2 years after OTC) |
AMH (ng/ml) | 2.73 | 1.18 | 1.3 | 2.54 | 3.70 |
FSH (IU/L) | 0 | 4.05 | 6.08 | 3.66 | 4.64 |
LH (IU/L) | 0 | 1.46 | 1.31 | 1.03 | 0.39 |
E2 (pg/ml) | 15000 | 11.8 | 11.8 | 33.67 | 19.37 |
AMH: anti-müllerian hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone; E2: estradiol; OTC: ovarian tissue cryopreservation |